Data from a large national surveillance study was used to describe antiretroviral regimens in pregnant women with HIV, with particular reference to the presence at conception of antiretroviral treatments contraindicated in pregnancy. Therapeutic changes during pregnancy were also analysed.
Results
Among 334 women on antiretroviral treatment at conception, less than half (42.4%) reported current pregnancy as planned. A large number of different regimens (80) was observed. All the regimens included at least one nucleoside or nucleotide reverse transcriptase inhibitor. Non-nucleoside reverse transcriptase inhibitors and protease inhibitors were present in similar proportions (39.2% and 40.7%, respectively). The most commonly used drugs were lamivudine (83.2% of regimens), zidovudine (50.0%), stavudine (d4T; 38.0%), nevirapine (25.7%), didanosine (ddI; 17.7%) and nelfinavir (17.7%). Treament with efavirenz (13.5% of regimens) and ddI+d4T (9.6%) was markedly frequent. Use of efavirenz at conception was associated with a subsequent treatment change during pregnancy (odds ratio [OR]: 13.2.; 95% confidence interval [CI]: 3.2–53.8, P<0.001). A similar but less strong association was found for ddI (OR: 1.8; 95% CI: 1.03–3.25, P=0.033), whereas being on nevirapine was associated with a lower risk (OR: 0.58; 95% CI: 0.38–0.81, P=0.013).
Conclusions
Our data show that treatment at conception frequently represents the regimen previously selected for the treatment of the non-pregnant woman. The observed rates of exposure to contraindicated treatment should lead prescribing physicians to consider in HIV-positive women therapeutic choices that take into account the likelihood of an unplanned pregnancy. Such an approach is likely to reduce not only unintended exposures to contraindicated drugs, but also therapeutic changes during pregnancy.
References
1.
AIDSinfo [homepage on the Internet].Rockville: U.S. Department of Health and Human Services [Updated 2005 Nov 17; cited 2006 Sept 26]. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available from: http://aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines.
2.
FloridiaM., RavizzaM., TamburriniE.Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy.Epidemiol Infect; in press.
3.
Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry Interim Report 1 January 1989 through 31 July 2005 [monograph on the Internet] [cited 2006 Sept 26]. Available from: http://www.apreg-istry.com/forms/APR_report_1205.pdf.
4.
FundaròC., GenoveseO., RendeliC.Myelomeningocele in a child with intrauterine exposure to efavirenz.AIDS, 2002, 16: 299–300.
5.
HittiJ., FrenkelL., StekA.- Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.J Acq Imm Def Syndr2004; 36: 772–776.
SarnerL., FakoyaA.Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication.Sex Transm Infect, 2002; 78: 58–59.
